



Date: June 9, 2023

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Completion of Inspection at Indoco Remedies Limited Baddi Plant-III

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that German Health Authority (Berlin) had inspected Company's Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi ("**Facility**"), from May 22, 2023 to May 25, 2023.

The Facility has received EU GMP certification from German Health Authority (Berlin) confirming that Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Please find enclosed herewith press release in this regard.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Indoco Remedies Limited

RAMANATHA
N
HARIHARAN
Digitally signed by
RAMANATHAN
HARIHARAN
Date: 2023.06.09
13:14:54 +05'30'



Ramanathan Hariharan

Company Secretary & Head- Legal



PRESS RELEASE

Indoco's Baddi facility receives EUGMP certification from Health Authority of Germany

Mumbai, June 9, 2023: Indoco Remedies has received EU GMP certification from the Competent Health Authority of Germany for its manufacturing site situated at HB 211 Village Katha, IN- 173 205 Baddi, Tehsil- Nalagarh, District - Solan. The Agency conducted an inspection at Indoco's manufacturing facility for oral dosage form (Baddi -III), from May 22 - 25, 2023.

The EU GMP certification issued by the German Health Authority (Berlin) confirms that the site complies with the Good Manufacturing Practice requirements as referred in the EC Directive. The EU certification will support supplies of drug products registered in Europe, from this manufacturing site.

Commenting on the development, **Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd.**, said that "The EU GMP certification for our site in Baddi adds to our consistent efforts to supply quality and affordable medicines in Europe. We are committed to being cGMP compliant and supplying quality products to our customers and patients across the globe."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company's turnover is US\$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries, please contact:

Pramod Ghorpade

Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com